(“Ananda” or the “Company”)
The directors of
Ananda owns 15% of LHT, the 100% owner of hapac®, a technology for inhaling medicinal cannabis.
As previously announced, the hapac® product was launched in
-- hapac® continues to be sold in 6 stores in
Italy-- rates of sale are positive and customer feedback sessions are ongoing to ensure the product experience and mix is optimised -- hapac® will be released in a wider range of CBD content and two new flavours in the coming weeks
Further information on the hapac® product can be found at http://hapac.tech.
The Board has been reviewing several investment opportunities which have the potential to significantly increase in value for the benefit of Shareholders. The Company looks forward to providing an update in due course.
The directors of the Company accept responsibility for the contents of this announcement.
Ananda Developments plc+44 (0)739 269 6517 firstname.lastname@example.org Executive Director Melissa SturgessInvestor Relations Jeremy Sturgess-Smith Peterhouse Capital Limited+44 (0)20 7469 0930 Corporate Finance Fungai Ndoro Mark AnwylCorporate Broker Lucy Williams Duncan Vasey
Notes to editors
Ananda Developments invests in the developing market for medical or therapeutic Cannabis derivatives, or related products, including but not limited to nutraceuticals, dietary supplements and cosmetic products which contain Cannabis or hemp derived cannabinoids. The Directors believe that this market is growing due to an increasing number of states in the
A copy of the Company’s Admission Document is available at www.anandadevelopments.com
Ananda’s investment strategy is to invest in companies, projects or products that are either progressing medical or therapeutic Cannabis research and development, or are developing or have already developed, products that contain Cannabis derived cannabinoids and require funding to progress work plans or commercialise products.